Abingworth life science investment
Company news

Press room

 


Company News

Novexel to be acquired by AstraZeneca
Paris, France, 23 December 2009
top
 
Zogenix Increases Series B Preferred Stock Financing to $71 Million, Raising $35 Million in Second Tranche
- Dr. Arda M. Minocherhomjee of Chicago Growth Partners Joins Zogenix Board of Directors -
San Diego, CA, 07 December 2009
top
 
Clavis Pharma and Clovis Oncology Sign $380 Million Partnership for the Development and Commercialisation of Anti-Cancer Agent CP-4126
Oslo, Norway, and Boulder, CO, 24 November 2009
top
 
Astex Announces Strategic Drug Discovery Alliance with GlaxoSmithKline
Astex’s world leading fragment chemistry platform, PyramidTM, to be used to identify novel compounds against multiple GSK target
Cambridge, UK, 12 November 2009
top
 
Prosensa and GlaxoSmithKline form alliance to fight Duchenne Muscular Dystrophy
Leiden and London, 13 October 2009
top
 
AMARIN ANNOUNCES $70 MILLION PRIVATE PLACEMENT
Dublin, Ireland, 13 October 2009
top
 
Ablynx and Domantis settle their dispute and stop the arbitration process
Ghent, Belgium, 12 October 2009
top
 
Sanofi-aventis to acquire Fovea Pharmaceuticals, a French biopharmaceutical ophthalmology company
Paris, France, 28 September 2009
top
 
Zogenix Closes $51 million in Series B Preferred Stock Financing and Prepares for January 2010 Launch Of SUMAVEL™ DosePro™
San Diego, CA, 23 September 2009
top
 
PrimeraDx closes $20m Series C
Company poised to introduce its unique quantitative multiplexed assay platform
Mansfield, Mass, 07 September 2009
top
 
Algeta signs $800 million (EUR 560m) global agreement with Bayer for development and commercialization of Alpharadin for bone metastases
Oslo, Norway, 03 September 2009
top
 
Avila Therapeutics Announces Agreement with Novartis to Develop Novel Covalent Drug Candidate
Waltham, MA, 27 July 2009
top
 
Avila Therapeutics, Inc. Closes $30 Million Series B Financing
Company to Advance Novel Class of Protein-Silencing Covalent Drugs into Clinic Development
Waltham, MA, 27 July 2009
top
 
Sumavel DosePro (sumatriptan injection) Approved by FDA for Acute Migraine and Cluster Headache
First Product Featuring Novel DosePro Needle-Free Delivery System
San Diego, CA, 16 July 2009
top
 
Merck & Co., Inc. and Portola Enter Worldwide License Agreement to Develop and Commercialize Betrixaban,
a Novel Investigational Oral Anticoagulant for Cardiovascular Disease
Whitehouse Station NJ and South San Francisco, CA, 09 July 2009
top
 
Intellikine Completes $51 Million Financing
La Jolla, CA, 08 July 2009
top
 
GSK and Chroma Therapeutics form alliance to develop novel macrophage-targeted drugs
London and Oxford, UK, 23 June 2009
top
 
Chroma Therapeutics completes £15 million Series D financing
Oxford, UK, 23 June 2009
top
 
Valeritas Announces Appointment of New CEO
Former Johnson & Johnson Senior Executive Kristine Peterson to Take Helm
Parsippany, NJ, 01 June 2009
top
 
Clovis Oncology Raises $145 Million in Start-Up Financing
New company founded by members of former Pharmion executive team
Boulder, CO, 20 May 2009
top
 
Algeta raises USD 35 million (NOK 245 million) in a Private Placement
Funds will be used to continue the development of Alpharadin for the treatment of bone metastases in a range of cancers
Oslo, Norway, 18 February 2009
top
 
Portola Pharmaceuticals Enters Worldwide License Agreement for Development and Commercialization of Novel Antiplatelet Drug
Portola to Receive $75 Million Upfront Cash Payment, $500 Million in Potential Milestone Payments Plus Royalties on Future Sales
South San Francisco, CA, 12 February 2009
top
 
Hydra Biosciences Raises $22 Million in a Series D Financing
Cambridge, Mass., 16 January 2009
top
 
Synosia Therapeutics Raises CHF32 Million in Series B Private Financing
Basel, Switzerland, 07 January 2009
top
 
Archive:
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
Andrew Kay, President and CEO of Algeta
Abingworth set a highly professional tone from the beginning. The due diligence was detailed and incisive and this attention to detail continued as Algeta became one of their portfolio companies. It is Abingworth's support capability that really distinguishes them. This includes market analytics, finance, commercial intelligence, and search expertise for executive managers and board members. They have extensive networks with big companies, biotechs and banks that provides invaluable introductions and contacts. What is quite remarkable is that despite being one of many portfolio companies, everyone across the Abingworth organisation seems to know who you are and they are responsive and enthusiastic about thinking of ways to help, identifying opportunities, issues and solutions.